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Abstract
Background: Cases of severe hypoglycaemia were reported in HIV/AIDS patients receiving high dose of the
sulfonylurea co-trimoxazole for opportunistic infections. Whether co-trimoxazole at prophylactic dose would induce
similar side effects is unknown. We aimed to investigate the acute effects of co-trimoxazole at prophylactic dose on
glucose metabolism in healthy adults.
Methods: We enrolled 20 healthy volunteers (15 males and 5 females) aged 23.0 (SD 2.0) years, with mean BMI of
22.3 (SD 3.6) Kg/m2 with normal glucose tolerance, hepatic and renal function. We performed a 75-g oral glucose
tolerance test (OGTT) with and without concomitant oral co-trimoxazole administered 60 min before the test. Blood
glucose response was measured using a capillary test at baseline and at 30, 60, 90, 120 and 180 min following oral
glucose load on the two occasions. C-peptide response was also measured. Absolute values of blood glucose and
C-peptide with and without co-trimoxazole were compared using the Wilcoxon test.
Results: During the OGTT without co-trimoxazole (control) vs. the OGTT with co-trimoxazole (test), the glycaemia
varied from 4.83 (SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44
(SD 0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs. 7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94)
mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78 (SD 1.00) mmol/l vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351)
and 4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180 (P = 0.747). The ratio of area under the glycaemia curve
during the control and test investigation was 96.7 %, thus a 3.3 decreased glycaemic response (p = 0.062). A decrease
of glycaemia by more than 10 % occurred in 6/20 participants at T30, 7/20 participants at T60 and 1/20 participant at
T30 and T60. None of the volunteers experienced co-trimoxazole-induced hypoglycaemia. At the same time, the
C-peptide response during the control vs. the test investigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8 (SD 42.5)
pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6) pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and 1049.8 (SD 503.1)
pmol/l vs. 1041.63 (SD 824.21) pmol/l at T180 (P = 0.893).
Conclusion: Ninety minutes after its administration, co-trimoxazole induced a significant reduction of the early
glycaemic response to oral glucose in parallel with a 27-% increase in insulin secretory response. Co-trimoxazole
induced within 120 min a more than 10-% blood glucose reduction in 2/3 of participants. However none of the
volunteers experienced hypoglycaemia.
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Background
The HIV/AIDS is a threatening condition affecting 31
million of persons in the world and which has been
responsible for 39 million of deaths since the beginning
of the pandemic (UNAIDS 2014). That condition leads
to a lowering of the immunity causing a high susceptibility
to infections. In HIV/AIDS patients the use of co-
trimoxazole for the treatment and prevention of
opportunistic infections is recommend and is associated with
a significant reduction in morbidity and mortality [1, 2].
Despite the inescapable place of co-trimoxazole in the
management of HIV/AIDS patients, its use is not risks
free [3]. It is responsible for a wide range of side effects
such as nausea, vomiting, allergic skin reactions and
hypoglycaemia [3]. Hypoglycaemia is an uncommon
complication of co-trimoxazole use, maybe for lack of
monitoring but, cases of severe hypoglycaemia were re-
ported in patients receiving high dose of co-trimoxazole
for opportunistic infections [4, 5]. Those hypoglycaemias
were concomitant to an increase in insulin secretion
what suggesting a sulfonylurea-like mechanism. Likewise
a study highlighted the hypoglycaemic potential of co-
trimoxazole in glipizide and glyburide users [6]. Whether
co-trimoxazole at prophylactic dose would induce simi-
lar side effects is unknown. The aim of this study was to
assess the acute glycaemic effects of co-trimoxazole at
prophylactic dose in healthy adults.
Methods
Setting and participants
The study was conducted at the National Obesity
Center, Yaounde Central Hospital. We enrolled 20
healthy adults, living in Yaounde (Cameroon) during the
study period; with no contraindication to co-trimoxazole
use and free of any medication for other purpose. Other
selection criteria included fasting blood sugar of less
than 7 mmol/l; Alanine Aminotransferase (ALAT) of
less than tree fold the normal; and a glomerular filtration
rate superior to 60 ml/min/1.73 m2 of body surface.
Procedure
Each participant underwent on two separated occasion a
75-g oral glucose tolerance test, with (test) and without
(control) oral administration of co-trimoxazole, 60 min
before the oral glucose load when indicated. The two
OGTT were separated by a period of 48 h and each par-
ticipant was his own witness. To minimise systematic
errors, one half of the participants started with the test
OGTT and the other half with the control OGTT. The
starting order was determined randomly. The co-
trimoxazole used was named BERLOCID, and were
manufactured by the MENARINI group in Berlin,
Germany. The tablets contained 960 mg of co-
trimoxazole. Blood glucose response was measured using
a OneTouch Ultra2 glucose meter at baseline and 30, 60,
90, 120 and 180 min following the oral glucose load on
the two occasions. The insulin response was also assessed
by a measure of C-peptide level at baseline, 60
and 180 min after the oral glucose load on the two
occasions. The c-peptide level was determined using the
MercodiaUltrasensitive C-peptide ELISA (Mercodia AB,
Sylveniusgatan 8A, SE-754 50 Uppsala, Sweden); based on
the direct sandwich technique in which two monoclonal
antibodies are directed against separate antigenic determi-
nants on the C-peptide molecule. This test has a detection
limit of 2.5 pmol/L and provides less than 1.8 % of cross
reactions.
Outcomes
The primary clinical outcome was a variation in blood
glucose response of more than 20 %, 2 h after the oral
administration of co-trimoxazole during the OGTT with
co-trimoxazole comparatively to the blood glucose
response during the OGTT without co-trimoxazole. The
secondary outcomes considered were a variation of more
than 10 % of the blood glucose response, any time after
the administration of co-trimoxazole and a variation of
the insulin secretory response during the OGTT with
co-trimoxazole comparatively to the OGTT without
co-trimoxazole.
Statistical analysis
Data was coded, entered and analyzed using the
Statistical Package for Social Science (SPSS) version 21.0
for Windows (IBM Corp. Released 2012. IBM SPSS
Statistics for Windows, Version 21.0. Armonk, NY: IBM
Corp.). We compared absolute value of blood glucose
response and C-peptide secretory response with the
non-parametric Wilcoxon test. A p value of less than
0.05 was considered statistically significant.
Results
Characteristics of the study population
We enrolled 20 volunteers aged 23.0 (SD 2.0), with
mean BMI of 22.3 (SD 3.6) kg/m2; mean fasting blood
glucose of 4.89 (SD 0.33) mmol/l; mean alanine amino-
transferase of 5.58 (SD 3.56) ui/l and a mean glomerular
filtration rate of 110.5 (SD 32.8) (Table 1).
Variations in the glycaemic response during the control
versus the test OGTT
During the control OGTT vs. the test OGTT, the glycaemia
varied from 4.83(SD 0.39) mmol/l vs. 4.72 (SD 0.28) mmol/
l at T0 (P = 0.667), to 8.00 (SD 1.11) mmol/l vs. 7.44 (SD
0.78) mmol/l at T30 (P = 0.048), 8.00 (SD 1.17) mmol/l vs.
7.67 (SD 1.00) mmol/l at T60 (P = 0.121), 7.33 (SD 0.94)
mmol/l vs. 7.11 (SD 0.83) mmol/l at T90 (P = 0.205), 6.78
(SD 1,00) vs. 6.67 (SD 1.00) mmol/l at T120 (P = 0.351) and
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4.72 (SD 1.39) mmol/l vs. 4.72 (SD 1.56) mmol/l at T180
(P = 0.747) (Table 2). The ratio of area under the glycaemia
curve during the control and test investigation was 96.7 %,
thus a 3.3 decreased glycaemic response (p = 0.062) (Fig. 1).
A decrease of glycaemia by more than 10 % occurred in 6/
20 participants at T30, 7/20 participants at T60 and 1/20
participant at T30 and T60.
Variations in the insulin secretory response during the
control versus the test OGTT
The C-peptide response during the control vs. the test in-
vestigation varied from 278.1 (SD 57.5) pmol/l vs. 242.8
(SD 42.5) pmol/l at T0 (P = 0.138), to 1845.6 (SD 423.6)
pmol/l vs. 2340.6 (SD 701.3) pmol/l at T60 (P = 0.345) and
1049.8 (SD 503.1) pmol/l vs. 1041.63 (SD 824.21) pmol/l
at T180 (P = 0.893) (Fig. 2).
Rate of co-trimoxazole induced hypoglycaemia
None of the participants experienced co-trimoxazole
induced hypoglycaemia.
Discussion
The co-trimoxazole is an antibacterial sulfonamide un-
avoidable in the management of HIV/AIDS patients but,
it sometimes induced severe and even protracted
hypoglycaemia when used in high dose. Our study aimed
to investigate the acute effects of co-trimoxazole at
prophylactic dose on glucose metabolism in healthy
adults. We noted an acute reduction in the glycaemic
response, with 70 % of the participants experiencing a
reduction of more than 10 % in the glycaemic response
during the test OGTT compared to the control OGTT,
some of them 90 min and others 120 min after co-tri-
moxazole administration. This reduction in glycaemic
response was concomitant to an increase in insulin
secretory response by 27 %.
Strevel and al. reported cases of severe and protracted
hypoglycaemia secondary to high doses of co-trimoxazole
in patients with hypoglycaemia risk factors [4, 5]. Those
risk factors include chronic renal failure (93 %), malnutri-
tion, and concomitant administration of propoxyphene.
Nunnari and al. also reported cases of hypoglycaemia sec-
ondary to high dose of co-trimoxazole. On the other hand,
Schelleman and al. highlighted co-trimoxazole induced
hypoglycaemia when associated to glipizide or glyburide
[6]. The absence of hypoglycaemia in our experimentation
could be related to our procedure. First we used a low
dose of co-trimoxazole; secondly we used a dynamic test
(a 75 g OGTT) which had the advantage to further stimu-
late the insulin secretion but at the same time prevent
hypoglycaemia. Furthermore, those hypoglycaemias
occurred in patients with others co-morbidities [4] or tak-
ing hypoglycaemic drug [4, 6] compared to our study
where volunteers had no co-morbidities and conserved
mechanism of counter regulation, which prevent
hypoglycaemia and which is probably responsible of the
trend to normalization 120 min after co-trimoxazole
administration. Indeed, in healthy person, the counter
regulatory mechanism are not only activated to reverse
hypoglycaemia but, also to prevent its occurrence. That
could justify the absence of hypoglycaemia signs. This is
correlated by the study of Natalie S. Schwartz and al.
which showed that the glycemic thresholds for activation
of glucose counter regulatory systems are higher than the
threshold for symptoms [7]. Thereby it would be
interesting to assess the hypoglycaemic potential of co-tri-
moxazole in patients with co-morbidities and altered
counter regulating mechanism.
Plausible mechanisms by which hypoglycaemia might
occur is the stimulation of insulin secretion as reported
by Nunnari and al. and Strevel and al. [4, 5], suggesting
a sulfonylurea-like mechanism. So co-trimoxazole
would fixed itself on the SUR1 subunit of the beta-cell
ATP-sensitive potassium channel leading to the closure
of ATP-sensitive potassium channels, then to the
depolarization of the cell membrane with the opening of
voltage-gated calcium channels. This produces an influx
of calcium that stimulates fusion of the docked insulin-
containing vesicles with the cell membrane and secre-
tion of insulin into the extracellular fluid by exocytosis.
Table 1 Baseline characteristics of the study population
Characteristics Mean values (SD)
Age 23 (2)
Sex (M/F) (15/5)
Body mass index (kg/m2) 22.3 (3.6)
Systolic bloc pressure (mmHg) 118 (11)
Diastolic blood pressure (mmHg) 75 (10)
Fasting blood glucose (mmol/l) 4.89 (0.33)
Alanine aninotranferase (IU/l) 5.58 (3.56)
Glomerular filtration rate (ml/min/1.73 m2) 110.5 (32.8)
SD standard deviation
Table 2 Variations in the glycaemic response during the control
versus the test OGTT
Glycaemia during control OGTT Glycaemia during Test OGTT
Time (minutes) Mean (SD) Mean (SD) Difference (%) p value
T-60 4.89 (0.33) 4.94 (0.28) −1.14 –
T0 4.83 (0.39) 4.72 (0.28) 2.30 0,667
T30 8.00 (1.11) 7.44 (0.78) 6.94 0,048
T60 8.00 (1.17) 7.67 (1.00) 4.17 0,121
T90 7.33 (0.94) 7.11 (0.83) 3.03 0,205
T120 6.78 (1.00) 6.67 (1.00) 1.64 0,351
T180 4.72 (1.39) 4.72 (1.56) 0 0,747
SD Standard deviation, Glycaemia are express in mmol/l and mean are
compared by the Wilcoxon test
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This is reinforced by the history of the discovery of
sulfonylurea. Indeed, Marcel Janbon reported cases of
reversible coma after glucose administration in patients
treated with the antibacterial sulphonamide 2254 RP for
typhoid fever. This finding aroused interrogations and
this is how A. Loubatières highlighted the hypoglycaemic
potential of 2254 RP.
This study shows that at prophylactic dose co-
trimoxazole can be safely administered in healthy adult,
and this is because of the activation of the counter regula-
tory system. Nevertheless a special attention should be
paid when co-trimoxazole is administered at high dose
like in the treatment of Pneumocystis jiroveci pneumonia,
and to patients with comorbidities including renal insuffi-
ciency or malnutrition. Indeed malnutrition and kidney
dysfunction are risks factors for severe hypoglycaemia in
patients using high dose of co-trimoxazole as reported by
Strevel and al. in a case series [4]. Moreover, Hemkisoy
and al. and Arem and al. reported a case of co-trimoxazole-
induced hypoglycaemia in a malnourish patient and in
another one with in chronic renal failure [8, 9]. A monitor-
ing of blood glucose level is advised in case of concomitant
administration of co-trimoxazole and sulfonylureas, in
order to rapidly detect and treat a potential hypoglycaemia
due an excessive insulin secretion, especially in patients
with relevant comorbidities.
Fig. 1 Test versus control OGTT: Compared glycaemic response. Caption: x-axis: time in minutes, y-axis glycemia in mmol/l
Fig. 2 Test versus control OGTT: compared C-peptide secretory response. Caption: x-axis: time in minutes, y-axis c-peptide in pmol/l
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Conclusion
Our study shows that 960 mg of co-trimoxazole reduce the
glycaemic response within 90 to 120 min after his adminis-
tration but no hypoglycaemia was observed (probably
related to the procedure). This reduction in glycaemic
response was associated with an increase in insulin
secretory response. Although ours finding cannot prove
nor exclude a co-trimoxazole induced hypoglycaemia at
prophylactic dose, we suggest to clinicians to be aware of a
hypoglycaemic potential of co-trimoxazole and thus
increase alertness, especially in patients receiving high dose,
with comorbidities or polymedicated patients.
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